Home
Elutia Inc.

Elutia Inc. Market Share Analysis for June 2026

VasCure is the natural method for vascular repair. With the use of SIS ECM, it conforms to the body's vascular anatomy to repair the defect.

Industry: N/A

Domainelutia.com

Year Founded2014

Employees51 - 200

Annual Revenue$10M - $15M

Elutia Inc.

Elutia Inc. (including company regionals)

elutia.com

See more website traffic and engagement information

Elutia Inc. Revenue up to June 2026 is 10M - 15M

revenue generated by Elutia Inc. top domains

Elutia Inc. top domains revenue over 3 years

Revenue for Elutia Inc. top domains

elutia.com10M - 15M

See more with Sales Intelligence

Total visits to Elutia Inc.'s top domains

Understand Elutia Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

elutia.com3.6K

See more with Sales Intelligence

Avg. visit duration in Elutia Inc.'s top domains

Analyze Elutia Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

elutia.com00:00:08

See more with Sales Intelligence

Avg. pageviews on Elutia Inc.'s top domains

See how Elutia Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

elutia.com1.41

See more with Sales Intelligence

Elutia Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Elutia Inc.

These are the website technologies, by industry, used by Elutia Inc. top domains

Advertising (5)

DoubleClick

Widget (3)

Slider Revolution

Mobile (2)

Meta Viewport

Audio Video Media (1)

YouTube

More Technologies

8

See all

News & Signals from Elutia Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsElutia Inc sold assets to Cellution Biologics Inc. in the amount of $8M on Jul 16th '26.Cellution Biologics Inc. signs definitive agreement to acquire SimpliDerm(R) human hydrated acellular dermal matrix business from Elutia Inc., expanding its allograft portfolio.

NewsElutia Inc is developing NXT-41x on Jul 16th '26.NXT-41x is being developed for the approximately $1.5 billion U.S. plastic and reconstructive surgery market, where Elutia believes antibiotic-eluting biomatrix technologies fulfill a significant unmet need in soft tissue reinforcement.

NewsElutia Inc attended event Planet MicroCap Showcase 2026 on Jun 17th '26.GAITHERSBURG, Md., June 11, 2026 (GLOBE NEWSWIRE) - Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Dr. Michelle Williams, Chief Scientific Officer, will present and host one-on-one meetings with investors at the Planet MicroCap Showcase 2026 at the Bellagio in Las Vegas, Nevada on June 17-18, 2026.